<DOC>
	<DOCNO>NCT00590824</DOCNO>
	<brief_summary>Evaluate antitumor activity hu14.18-IL2 minimal residual disease set . Evaluate time recurrence overall survival patient treat hu14.18-IL2 .</brief_summary>
	<brief_title>Pilot hu14.18-IL2 Resectable Recurrent Stage III Stage IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion 1 . Subjects must recurrent stage III ( i.e. , recurrent regional metastasis ) , stage IV ( i.e. , distant metastasis ) melanoma surgical resection would clinically recommend , biopsy proven ( current previous ) Stage III Stage IV disease . Any biopsy obtain demonstrate recurrent regional metastasis distant metastasis must consider clinically appropriate clinical management must perform solely meet eligibility criterion . In addition , subject must disease yet completely excise . 2 . Patients must disease involve 3 few site . A nodal basin recurrence score one site , even multiple node positive . `` Clustered '' subcutaneous and/or cutaneous lesion remove single surgical excision score one site , even multiple subcutaneous and/or cutaneous lesion present . 3 . The subject ' disease determine completely resectable uninvolved margin use standard surgical guideline base physical exam radiographic imaging ( MRI CT head , CT MRI chest , abdomen pelvis ) . 4 . Subjects must one following : ) Stage III melanoma recurrence prior surgery , without subsequent adjuvant systemic ( standard experimental ) and/or radiotherapy management Or b ) Stage IV melanoma ( cutaneous , ocular , mucosal , unknown primary ) 5 . Subjects must 18 year old old OR 15 year old great , consider mature minor , able give adult inform consent ( parental cosignature ) , meet eligibility criterion , also weigh least 45 kg.. Subjects must weigh least 45 kg order safely provide sufficient blood monitoring study ( see section 7.7 detail ) . 6 . Subjects must ECOG performance status 0 1 . 7 . Subjects must adequate bone marrow , liver , renal function . 8 . Subjects one follow cardiac risk factor must complete stress radionuclide scan evidence myocardial ischemia heart failure : ( ) history cardiac disease , ( b ) age great 65 year old , ( c ) clinically significant abnormality find ECG ( require baseline ) , ( ) significant risk factor coronary artery disease ( history significant dyslipidemia ; treatment dyslipidemia ; two first degree relative document myocardial infarction prior age 55 ) . 9 . Subjects significant history pulmonary disease , shortness breath rest , know COPD must pulmonary function test within 35 % normal agepredicted value . 10 . Subjects must willing able provide inform write consent prior studyrelated procedure . 11 . Subjects must immediate requirement palliative chemotherapy , palliative radiotherapy , palliative hormonal therapy . 12 . Subjects must willing able discontinue antihypertensive medication advise day hu14.18IL2 infusion . 13 . Subjects must slide available stage III stage IV melanoma . Paraffin block preferable , minimum , slide document melanoma biopsy ( include fine needle cytology ) must available pathology review , potential restaining/staining ( see Section 7.4 , Surgical Pathology Guidelines ) . Prior histologic demonstration metastatic melanoma ( either stage III Stage IV ) may utilized repeat biopsy clinically need establish eligibility . Exclusion criteria 1 . Subjects ineligible receive mAbs biologic therapy , tumor imaging , purge autologous marrow/stem cell reinfusion reason unless serological testing perform . If absence detectable antibody ( background ) hu14.18 document , subject eligible study . 2 . Subjects treat IL2 past develop intolerable ( Grade 4 ) IL2related side effect eligible . 3 . Subjects receive ( standard experimental ) systemic therapy stage IV disease eligible . 4 . Women childbearing potential exclude pregnant , nursing , use effective contraception treatment period . 5 . Subjects symptoms ischemic cardiac disease , congestive heart failure , myocardial infarct within immediate precede 6 month and/or uncontrolled cardiac rhythm disturbance ineligible . 6 . Subjects significant psychiatric disability seizure disorder ineligible . 7 . Subjects major surgery within past 3 week ineligible . 8 . Subjects clinically detectable pleural effusion ascites ineligible . 9 . Subjects organ allograft ineligible . 10 . Subjects require likely require corticosteroid immunosuppressive drug use within 2 week registration ineligible . 11 . Subjects significant intercurrent illness ineligible . 12 . Subjects active infection active peptic ulcer unless condition correct control ineligible . 13 . Subjects brain metastasis , whether active inactive , ineligible . A head MRI head CT scan require baseline rule silent metastasis . 14 . Subjects active second malignancy nonmelanoma skin cancer ineligible . Patients consider eligible continuously disease free &gt; 5 year prior time enrollment . 15 . Subjects infected human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBs Ag ) carrier state clinical evidence hepatitis ineligible . Treatment may initiate laboratory confirmation HIV HBs Ag negativity , stop result positive . 16 . Subjects clinically significant neurologic deficit objective peripheral neuropathy ( Grade &gt; 2 ) ineligible . 17 . Subjects know hypersensitivity study drug , Tween80Â® human immunoglobulin ineligible . 18 . Patients known history diabetes mellitus require systemic therapy within past 3 month ( either oral hypoglycemic agent insulin ) exclude , treatment hu14.18IL2 may alter blood glucose level . 19 . Subjects legal incapacity limited legal capacity ineligible . 20 . Subjects bone metastases ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>hu14.18-IL2</keyword>
</DOC>